Reporting from Madrid — On Oct. 23, 2026, STAT reported that data from a highly anticipated Moderna-Merck melanoma cancer vaccine presentation had been released ahead of its scheduled appearance at the European Society for Medical Oncology conference. The outlet’s account said the early disclosure constituted an embargo violation and occurred on the eve of the meeting, upending plans for presenters, conference organizers, and journalists.
Andrew Joseph and Adam Feuerstein, the STAT reporters on the story, wrote that the organization itself was not responsible for the premature release. The full article was published from Madrid and flagged that more detailed coverage is accessible through STAT’s subscriber service, STAT+.
According to the STAT piece, the leak involved data that conference organizers and reporters had considered the most anticipated information at ESMO that year. The early release surprised many attendees and disrupted the normal cadence of embargoed scientific presentations.
The article emphasized the practical consequences of the breach for reporters: carefully planned coverage and embargoed reporting schedules were thrown off as the leaked material circulated before its scheduled presentation slot at the conference. STAT noted its own position explicitly, stating it was not the source of the embargo violation.
Scientific conferences like ESMO routinely use embargoes so researchers, journalists, and the public can receive detailed information at the same time and with appropriate context from presentations and accompanying publications. When embargoes are broken, organizers and journalists lose that coordinated moment, and audiences may receive partial or out-of-context information.
In this case, the leaked material related to a collaboration between two major biopharma companies, Moderna and Merck, and concerned a vaccine aimed at melanoma, a form of skin cancer. STAT framed the data as the conference’s most closely watched item, which helps explain the strong reaction to the leak.
The Oct. 23 story carried by STAT laid out the circumstances of the embargo breach and the reporters’ immediate reactions. The article made clear that a larger, detailed account of the data and its implications was being presented in a subscriber-only STAT+ article.
The publicly available portion of the story does not include the complete data from the Moderna-Merck presentation, nor does it provide full details of the trial results or clinical endpoints. STAT directed readers to its STAT+ service for the extended coverage and analysis.
Moderna and Merck have both been active in cancer research and vaccine development. Major oncology meetings such as ESMO often host presentations of late-stage and high-profile trials, and news from those presentations can affect researchers, clinicians, patients, and investors. The leak of a headline dataset at that moment raised immediate concerns about the quality of information flow around the conference and about how embargoed data are protected and distributed in the run-up to sessions.
The STAT piece—filed from Madrid by Andrew Joseph and Adam Feuerstein—placed the leak in that setting and stressed the disruption caused to reporting plans when an embargo is broken.
The article described heightened frustration among reporters who had prepared for embargoed coverage and noted the scramble that followed the early release. STAT explicitly stated it was not the party responsible for the violation. Beyond that statement and the account of the disruption, the public portion of the story did not provide additional detail on reactions from the conference organizers, the companies involved, or independent experts; such material was indicated as part of the subscriber-exclusive coverage.
STAT’s free summary did not include the full trial data or a detailed analysis of the vaccine findings. It did not report any specific clinical results, numerical outcomes, safety information, or company comments in the publicly available text. For readers seeking the complete dataset, in-depth analysis, or quoted responses from Moderna, Merck, or ESMO officials, STAT directed readers to its subscriber product, STAT+.
An embargo breach around the Moderna-Merck melanoma vaccine presentation at ESMO created immediate disruption on the eve of the conference. STAT’s reporting on Oct. 23, 2026, noted the early release as a significant violation of standard conference practice, emphasized that STAT was not the source of the leak, and indicated that comprehensive details and analysis of the data are available in a subscriber-only article. The public summary leaves key questions about the trial results and formal responses from involved parties unanswered in the free report.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.